
Eupraxia Pharmaceuticals rose 11.2% from $6.60 to $7.34, ahead of the S&P 500's +11.2%. Its worst day was Oct 1 (−14.0%), and its low came Jul 24 at $5.81.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health.
+19.1%, the year's best day · S&P 500 0.0%
Story events cover the past 12 months · Times ET
Eupraxia Pharmaceuticals shares rose 15.1%, while the S&P 500 fell 0.8%.
+15.1% · S&P 500 −0.8%
EPS of $-0.37 missed the $-0.16 estimate on $0.00 revenue.
−1.9% · S&P 500 −0.6%
EPS of $-0.23 missed the $-0.20 estimate on $0.00 revenue.
−0.8% · S&P 500 +0.6%
Eupraxia Pharmaceuticals closed at its lowest level of the year, 12.0% below where the year started.
−7.8% · S&P 500 +0.1%
EPS of $-0.23 beat the $-0.23 estimate on $0.00 revenue.
−3.3% · S&P 500 +0.3%
Eupraxia Pharmaceuticals shares rose 17.5%, while the S&P 500 rose 0.4%.
+17.5% · S&P 500 +0.4%
Eupraxia Pharmaceuticals closed at its highest level of the year, 37.9% above where the year started.
+9.6% · S&P 500 −0.2%
EPS of $-0.23 beat the $-0.26 estimate on $0.00 revenue.
+5.6% · S&P 500 +1.3%
Where it ended: a close of $7.34 on Nov 16, 2026. Up next: Q4 2026 earnings on Mar 11, 2027 (EPS est. $-0.26).
Nothing in the past 12 months.
All EPRX dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for EPRX and SPY from Benzinga historical bars. Not investment advice.